Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Sep;97(9):e34-5.
doi: 10.3324/haematol.2012.067629.

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Katja Sockel, Martin Bornhaeuser, Eva Mischak-Weissinger, Rudolf Trenschel, Martin Wermke, Christian Unzicker, Guido Kobbe, Jürgen Finke, Ulrich Germing, Brigitte Mohr, Jochen Greiner, Dietrich Beelen, Christian Thiede, Gerhard Ehninger, Uwe Platzbecker; German MDS and Cooperative Transplant Study Group (GCTSG)
Comment

Lenalidomide maintenance after allogeneic HSCT seems to trigger acute graft-versus-host disease in patients with high-risk myelodysplastic syndromes or acute myeloid leukemia and del(5q): results of the LENAMAINT trial

Katja Sockel et al. Haematologica. 2012 Sep.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Möllgård L, Saft L, Treppendahl MB, Dybedal I, Nørgaard JM, Astermark J, et al. Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities. Haematologica. 2011;96(7):963–71. - PMC - PubMed
    1. van der Straaten HM, van Biezen A, Brand R, Schattenberg AV, Egeler RM, Barge RM, et al. Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities. Haematologica. 2005;90(10):1339–45. - PubMed
    1. Ferrant A, Labopin M, Frassoni F, Prentice HG, Cahn JY, Blaise D, et al. Karyotype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation study. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) Blood. 1997;90(8):2931–8. - PubMed
    1. Platzbecker U, Mohr B, von Bonin M, Binder M, Schetelig J, Ehninger G, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia. 2007;21(11):2384–5. - PubMed
    1. Platzbecker U, Wermke M, Radke J, Oelschlaegel U, Seltmann F, Kiani A, et al. Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia. 2012;26(3):381–9. - PMC - PubMed

MeSH terms